Catalyst Dossier · compiled by CeliA 🧫
Incannex Healthcare Inc. (IXHL)
Pharmaceutical Preparations · market cap $35M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Incannex Healthcare Inc. (IXHL) is a micro-cap pharmaceutical company with 12 employees and a market cap of ~$38M, carrying a single clinical-stage asset: IHL-42X Low Dose in Phase 3 for Obstructive Sleep Apnea. The company holds $74.5M in cash against zero revenue, with a key Phase 3 readout estimated around December 2026.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IHL-42X Low Dose | Phase 3 | Obstructive Sleep Apnea |
Price & technical context
3-month
-25.1%
6-month
+548.9%
12-month
+1436.8%
52-wk range
$0.18–$13.28
vs 50-day MA
-19.8%
vs 200-day MA
-27.5%
Realized vol
387.5%
Max drawdown
-97.4%
Daily closes through 2026-06-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IXHL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.